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Abstract
Background: The frontiers of clinical medicine constantly expand as a result of the innovative efforts of visionary researchers and keen observations of seasoned
clinicians. In medicine, rarely has a therapeutic agent been found efficacious in the management of so many symptoms and in such a relatively short time as
botulinum toxin. One of the most notable contributions of botulinum toxin therapy in clinical medicine is in the field of movement disorders.
Methods: The English literature was searched using the Yale search engine including but not limited to PubMed and Ovid. The search includes articles from
January 1 1980 to March 1 2016.
Results: A total of 2055 articles were identified. Of these, 132 met the criteria for this review.
Discussion: This historical review highlights early and seminal contributions that have introduced the application of botulinum toxins in the field of movement
disorders and provides evidence-based contributions that have established botulinum toxin as an effective treatment for abnormal movements.
Keywords: Movement disorders, dystonia, botulinumtoxin, onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, rimabotulinum toxinB
Citation: Jabbari B. History of botulinum toxin treatment in movement disorders. Tremor Other Hyperkinet Mov. 2016; 6. doi: 10.7916/D81836S1
* To whom correspondenrce should be addressed. E-mail: bahman.jabbari@yale.edu
Editor: Elan D. Louis, Yale University, USA
Received: April 8, 2016 Accepted: October 25, 2016 Published: November 28, 2016
Copyright: ’ 2016 Jabbari. This is an open-access article distributed under the terms of the Creative Commons Attribution–Noncommercial–No Derivatives License, which permits the




Conflict of Interest: The author reports no conflict of interest.
Ethics Statement: Not applicable for this category of article.
Introduction
Botulinum toxin, produced by Clostridium botulinum is a potent toxin
capable of rendering therapeutic effects based on its specific synaptic
physiology. While playing at a funeral on December 14, 1897, a group
of 34 Belgian musicians consumed smoked ham and developed visual
and gastrointestinal symptoms characteristic of botulism; three of the
34 died. The remaining ham and some of the deceased organs were
sent to Emile van Ermengem, professor of bacteriology at the
University of Ghent.1 He found the responsible agent and named it
Bacillus botulinum after the Latin word of botulus for sausage. In early
20th century, the word Clostridium (spindle shape) replaced the word
Bacillus (Clostridium botulinum). During the latter years of World War II,
Carl Lamanna and Edward Schantz isolated and purified the toxin in
the US Army facility of Fort Dietrich, Maryland. In 1946, Schantz
produced a large volume of the purified toxin and continued his
research at the University of Wisconsin with Eric Johnson and other
co-workers. In 1965, Drachman2 demonstrated paralysis and atrophy
of chick’s muscles after botulinum toxin injection, a finding that
encouraged Allan Scott, an ophthalmologist, to investigate it further
for treatment of strabismus. Dr. Scott’s research during the 1960s and
1970s led to Food and Drug Administration (FDA) approval for
conducting human research using the toxin for treatment of strabismus
(1979). Ultimately, the FDA approved the use of Schantz toxin (then
called oculinum) for treatment of strabismus, blepharospasm, and
hemifacial spasm (HFS) in 1989. Over the next 26 years, research
exploded in this area; different toxins were developed and botulinum
toxin was approved for several other movement and autonomic dis-
orders including cervical dystonia (CD), hyperactive bladder, sialorrhea,
hyperhidrosis, migraine, and spasticity.
Botulinum toxin has eight major serotypes designated as A, B, C, D,
E, F, G, and H. Only type A and B are used in clinical practice
because of their longer period of action. The molecular weight of
150 kDa for the core toxin plus surrounding proteins (ranging from
500 to 900 kDa) does not allow absorption of the toxin complex
through the skin. The toxin’s core consists of a light chain (50 kDa) and
a heavy chain (100 kDa) attached together by a disulfide bond. After
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intramuscular injection, tissue protease nicks the toxin and detaches
the toxin molecule from the protein complex within minutes.3 The
heavy chain of the toxin attaches the toxin to the outer surface of
the presynaptic membrane at specific polysialogangioside receptors.
The toxin then enters the vesicles by endocytosis. Once inside the
vesicle, the low pH helps the toxin to enter the lipid layer of the vesicle
wall. The heavy chain translocates the light chain from the vesicle into
the cytosol and it then attaches to the target SNARE proteins (soluble
N-ethylmaleimide sensitive fusion protein attachment receptor pro-
teins).4 These proteins are specific peptides that constitute the main
machinery of vesicle fusion into the synaptic membrane, vesicle rupture,
and release of the neurotransmitter.5 The SNARE protein SNAP 25
was first identified by Yale investigators as the site of attachment of
type A toxin’s light chain.6 The light chain, a zinc-activated peptidase,
then catalyzes the peptide structure of SNARE protein preventing vesicle
fusion and rupture. For the type B toxin, the SNARE protein is attached
to the surface of the vesicle itself (VAMP, vesicle attached membrane protein).
Currently three type A and one type B toxin are approved by the
FDA for clinical use in the United States. The type A toxins are Botox
(onabotulinumtoxinA) produced by Allergan Inc., Xeomin (incobotuli-
numtoxinA) from Merz Pharma, and Dysport (abobotulinumtoxinA)
from Ipsen. The type B toxin, Myobloc (rimabotulinum toxin) is pro-
duced by Solstice/US World Meds. In comparator clinical trials sometimes
unit comparisons are used (1 onabotulinum toxin unit51 incobotulinum
toxin unit53 abobotulinum toxin units540–50 units of rimabotulinum
toxin. However, there is significant individual variability and weakness does
not necessarily predict the desired clinical effect.
There are other differences among these toxins. For example,
incobotulinumtoxinA has less immunogenicity than other toxins and
does not need to be refrigerated (recommended by the manufacturer
for the other two type A and the type B toxins). RimaboutlinumtoxinA
comes as a prepared solution, whereas the other three toxins come as
powders in a vial and require dilution with preservative-free saline
before injection.
Search method
For this historical review, the author searched the English literature
using the Yale search engine including but not limited to PubMed and
Ovid. The search includes articles from January 1 1980 to March 1
2016. The search terms consisted of botulinum toxin or botulinum
neurotoxin plus the following terms: history, movement disorder,
dystonia, blepharospasm, laryngeal dystonia, task-specific dystonia,
HFS, tremor, chorea, tics, Tourette syndrome. Additionally, botuli-
num toxin plus three uncommon movement disorders were also
searched: spinal myoclonus, painful/painless legs moving toes, and
painful/painless arm moving fingers.
The search identified a total of 2,055 articles published from
January 1 1980 to March 1 2016, 132 of which met the criteria defined
for this review. The criteria for selection consisted of 1) manuscripts
that described the history of botulinum toxin discovery and predicted
its clinical usefulness; 2) manuscripts that provided early descriptions of
molecular structure and mechanism of function; 3) manuscripts that
pioneered application of botulinum toxins in movement disorders;
4) review articles of historical significance that provided information
regarding the development of new applications or clinical extension of
old applications.
Results
A brief historical note
Justinus Kerner (1786–1862), a German physician, is credited as
being the first to recognize the potential of botulinum toxins for treat-
ment of hyperkinetic movement disorders and conditions of autonomic
dysfunction. Kerner’s observations and contributions are described in
a series of recently published articles by Erbguth and Naumann.7–9 In
brief, Kerner, who witnessed several outbreaks of botulism after
consumption of smoked sausage, described in detail symptoms of 76
and 155 patients in two seminal articles published in 1820 and 1822.
He believed a fat poison, most likely biologic and not environmental,
was responsible for the patients’ illness. Considering the patients’
symptoms of weakness, dry mouth, and reduction of body secretions,
Kerner predicted that the sausage/fat toxin had a potential to alleviate
symptoms of muscle hyperactivity or those symptoms caused by
‘‘hyperexcitabiliy of the sympathetic nervous system.’’
History of botulinum toxin treatment in common movement
disorders
Dystonia. Dystonia is a neurologic syndrome characterized by
involuntary sustained, patterned, and often repetitive muscle contrac-
tions of opposing muscles causing twisting or spasmodic movements or
abnormal postures.10 Treatment of dystonic symptoms with botulinum
toxins is now a major area of medical practice.
Blepharospasm. Blepharospasm is a focal dystonia of orbicularis oculi
muscles that leads to frequent blinks and, in severe cases, forced
closure of the eyes. In one study, the average age of onset of essential
blepharospasm was between the fifth and sixth decades, with a female
to male ratio of 2.8:1.11 Blepharospasm responds well to antic-
holinergic medications, but a satisfactory response may require high
doses (exceeding 30 mg/day for trihexyphenidyl), resulting in memory
loss and confusion which is poorly tolerated by elderly people.
In 1984, Frueh et al.12 reported a positive response lasting for
10 weeks in ‘‘most of the 22 patients with blepharospasm’’ who were
injected with botulinum toxin A (then called oculinum). In the following
year, Scott et al.13 described 39 patients with blepharospasm who were
followed for up to 170 days with repeated periocular oculinum injections;
all responded. In the same year, a group from Columbia University in
New York14 supported Scott’s observation via their positive findings in a
small blinded study of five patients. Another small, blinded study from
Baylor College of medicine on 12 patients (in 1987) demonstrated similar
positive results.15 Over the next few years several large open clinical
observations reported excellent results with Botox in the treatment of
blepharospasm. Professor Fahn quotes a personal communication with
Dr. Scott in 1990 in which Dr. Scott described very good results with
treatment of nearly 2,000 patients.16 In 1989, based on these vast
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observations, the FDA approved treatment of blepharospasm with
onabotulinum toxin A despite the lack of class I or II blinded studies at
that time.
In the most recent review of botulinum toxin treatment of
blepharospasm, Karp and Alter17 define botulinum toxin as the first
line of treatment for blepharospasm with an efficacy rate of over 90%
based on the accumulative literature. Botulinum toxins are effective in
both essential and secondary blepharospasm. Experience of up to
26 years has demonstrated continued efficacy with repeated injections,
although a small increase in the dose may be necessary over time to
maintain the same level of efficacy.17,18 The most recent guidelines of
American Academy of Neurology19 assigns level B evidence (probably
effective) to incobotulinumtoxinA and onabotulinumtoxinA toxins and
a level C evidence (possibly effective) to abobotulinumtoxinA for
treatment of blepharospasm. It states, however, that in view of most
experts in the field of movement disorders, botulinum toxins are
considered the first line of treatment for blepharospasm.
Hemifacial spasm. HFS is not a dystonia but it is placed here due to its
semeiologic and regional similarities to blepharospasm. Babinski
coined the term hemifacial spasm (hemispasme facial) in 1905 but
the condition had been described earlier by others (Schultze 1875,
Gowers 1885).20 A prevalence of 11 in 100,000 had been reported for
HFS, with female to male predominance of 2:1.21,22 HFS involves one
side of the face with focus around the eye and, in many patients, there
is also involvement of the ipsilateral facial muscles close to the corner
of the mouth. In most cases, the cause is an anomalous and ectatic
blood vessel that impinges upon the facial nerve as it exits from the
brain stem. Treatment with anticonvulsants and clonazepam can be
partially effective.17 Neurovascular decompression is effective in most
cases, but in some cases it can cause serious morbidity.
The efficacy of type A toxin (oculinum/Botox) in HFS was first
reported in three patients in 1984,12 and subsequently in another open
observation of 15 patients in 1985.23 Subsequent observations in a
large number of open studies with a sizeable number of patients
strongly supported the efficacy of botulinum toxins in HFS. The FDA
approved onabotulinumA for treatment of HFS in 1989. Recently,
Hallett et al.24 have evaluated the efficacy of botulinum toxins in
movement disorders using the efficacy criteria of the American
Academy of Neurology.25,26 The level of efficacy for botulinum toxin
treatment in HFS was designated as B, probably effective, based on
two double-blind, class II studies.27,28 The data were available only for
onabotulinumtoxinA and abobotulinumtoxinA. OnabotulinumtoxinA
was given a level B efficacy based on two level II studies, and abo-
botulinumtoxinA a level C efficacy, possibly effective, based on one
level II study. However, these class C and B studies had several
limitations, including a lack of concealment, a small number of
participants, a single blind design, and a high rate of patient dropouts.
It is currently believed that botulinum toxin treatment is the treatment
of first choice in HFS. Long-term data have shown that 76–100% of
patients demonstrate at least 75% improvement of their symptoms
after botulinum treatment.17
Cervical dystonia. CD is the most common form of focal dystonia with
a prevalence of five out of 100,000 cited in some studies.29 In a recent
large study, the mean age of onset was 49 years and 74% of the
patients were female.30 The percentage of different forms of CD was as
follows: torticollis (rotational posture) 47.5%, laterocollis (lateral tilt)
38.9%, antecollis (anterior bent) 5.7%, and retrocollis (posterior bent)
5.3%. Limitation of head rotation, usually one side more than the
other, is one of the hallmarks of torticollis. Torticollis is sometimes
associated with head jerks that are intensified when the head is rotated
toward the direction of limitation (named by some myoclonic
dystonia). Before introduction of botulinum toxins, anticholinergic
drugs such as trihexyphenidyl (Artane) and benztropine were the most
effective treatment. However, their utility is limited, particularly in
older individuals because of frequent onset of memory loss, delusions,
and visual hallucinations. Clonazepam is effective in reducing the
myoclonic head jerks in CD.
In 1985 and 1986, Tsui and co-workers31,32 first reported on the
efficacy of botulinum toxin A in CD. Their first article, an open study,
demonstrated an improved range of head movement and neck pain
after Botox injection into the neck muscles of 12 patients. The second
article, a double-blind, placebo-controlled trial of 21 patients, showed
that onabotulinumtoxinA treatment produced subjective and objective
improvement as well as pain relief in 63%, 53%, and 88% of the
patients, respectively. For the placebo group, the same improvement
figures were 35%, 15%, and 24%.
Over the next 10 years a number of class II and class III double-
blind studies suggested the efficacy of botulinum toxins in CD. In one
such class II study, Greene et al.33 demonstrated further improvement
of CD symptoms after second injection. The initial rate of 67% rose to
74% after a second treatment during the extended open phase.
The first class I study of botulinum toxin treatment of CD was
reported by Lew et al.34 for type B toxin in 1997. The investigators
tested 122 patients in a double-blind, placebo-controlled protocol. The
type B injected group received two total doses of 2500 and 5000 units.
The primary outcome at 4 weeks was improvement in the Toronto
Western Spasmodic Torticollis Rating Scale. There was a significant
difference between the two groups in favor of botulinum toxin B.
Bledso and Comella’s35 recent review identified a total of eight class
I, double-blind, placebo-controlled, multicenter studies assessing the
efficacy of different botulinum toxins in CD. The authors also included
five additional comparator studies in this report. To date, there is one
class I, placebo-controlled study for onabotulinumtoxinA, three
placebo-controlled and two comparator studies (one with trihexiphe-
nidyl and one with Botox) for abobotulinumtoxinA, one placebo-
controlled and one comparator study (with onabotulinumtoxinA) for
incobotulinumtoxinA, and three placebo-controlled and two com-
parator studies (with onabotulinumtoxinA) for rimabotulinumtoxinB.
The results have consistently shown efficacy of all four toxins in CD.
On the basis of these data, a group of experts designated a level A
efficacy (established, effective) for all four botulinum toxins (three type
A and one type B) for CD treatment.23 The FDA approved rim-
abotulinumtoxinB and onabotulinumtoxinA in the year 2000 and
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abobotulinumtoxinA and incobotulinumtoxinA in 2009 for CD
treatment in the United States.
Task-specific dystonia. Task-specific dystonias are a group of focal
dystonias in which dystonic posturing and contractions of certain
muscles occur during specific acts and lead to motor dysfunction. The
existence of task-specific dystonia was recognized by astute clinicians in
the 19th century. Charles Bell (1830) described cases of dystonic
writer’s cramp and Gowers (late 1800s) reported cases of musicians’
dystonia.36 Cohen et al.37 studied electromyography (EMG)-guided
injection of onabotulinumtoxinA in 19 patients with TSD, 12 of
whom had dystonic writer’s cramp and five who had musician’s
dystonia (piano and guitar players). Sixteen of the 19 patients showed
improvement of function. Their finding is consistent with 60–70%
improvement that was found in three small, class II blinded studies
with onabotulinumtoxinA conducted a few years later38–40 and a more
recent double-blind class I study using abobotulinumtoxinA for
writer’s cramp/dystonia.41 Hallett et al.42 provided a comprehensive
review of botulinum toxin treatment in focal hand dystonia, including
that of musicians and dystonic writer’s cramp. Many patients with
musician’s dystonia also report some improvement of performance
after treatment, but most subjects are not able to achieve their
previous/initial level of precision. Hand weakness is a common side
effect but is not often disabling. Lungu et al.43 reported on 10 years or
longer follow-up of 20 patients with dystonic writer’s and musician’s
cramp. The patients tolerated the repeated injections well. The
continued response with repeated injections over such a long time
reflected low immunogenicity.
Laryngeal dystonia (spasmodic dysphonia). Laryngeal dystonia is a form
of task-specific dystonia. The appearance of the vocal cords is normal,
but vocal cords either over-adduct or over-abduct during talking. In the
adductor type, the patient’s voice is strained and strangled, whereas the
abductor type produces a breathy and whispering voice.44 Overactivity
of the thyroarytenoid muscle is responsible for the more common
adductor type, whereas contractions of the posterior cricoarytenoid
muscle causes abductor laryngeal dystonia. Andrew Blitzer, an oto-
laryngologist, was first to inject botulinum toxin A into the vocal cord
muscles for treatment of laryngeal dystonia in 1984.45 Since then, over
50 publications reported positive results in this area. Blitzer et al.46 have
recently reported their experience over a period of 30 years with 901
patients suffering from laryngeal dystonia. The mean age of the patients
was 39 years: 63% were female, 82% had adductor, and 17% had the
abductor type of laryngeal dystonia. Over 90% of the patients res-
ponded to treatment with the level of voice improvement reported by
the patients as 70.3% for adductor and 55% for abductor dystonia.
Bilateral injection with approximately 1 unit (in the case of onabotuli-
numtoxinA) is recommended for adductor dystonia. For unilateral
injection, the required dose is more (up to 3.75 units). Injections are
through a hollow EMG needle after EMG-guided identification of the
muscle. Despite the lack of blinded studies, botulinum toxin injection
into the vocal cord muscles is now considered the first approach for
management of laryngeal dystonia because of the high rate of success.
A low and breathy voice for days after injection is the most common side
effect; however, patients in general tolerate this inconvenience for
experiencing a remarkable voice improvement that can last for 3–6
months.
Tremor. Tremor is a rhythmic, oscillatory movement that is caused by
involuntary contraction of the agonist/antagonist muscles. It can be
classified into rest and action tremor. Action tremor includes four
types: postural, kinetic, task-specific, and isometric tremor. Lotia and
Jankovic47 have recently reviewed the role of botulinum toxins in the
management of different tremors.
Essential tremor
In 1991, Jankovic and Schwartz48 first reported the effect of
onabtulinumtoxin A in 34 patients with essential tremor in an open
observation. Tremor improved in 67% of the patients, but 60%
demonstrated hand weakness following injection into arm flexors and
extensors. To date, two double-blind placebo-controlled studies have
been conducted in this area. Both studies have used a fixed-dose
injection design. The first study investigated 25 patients in 1996.49 The
patients were injected with a total of 50 units of onabotulinumtoxinA
into two wrist flexors and two wrist extensors. If there was no
appreciable response within 4 weeks, a second injection of 100 units into
those muscles was employed. Although there was no statistically
significant difference between the toxin and placebo groups, the toxin
group showed subjective improvement of tremor with 75% of the
patients demonstrating a two-grade improvement in the tremor scale.
Between 42% and 50% of the patients developed hand weakness but it
was non-disabling. The second study50 was multicenter, fixed dose, and
parallel design, and was conducted on 133 patients. Two groups of low
dose (50 units) and high dose (100 units) of onabotulinumtoxinA were
compared with placebo. There was a statistically significant difference in
terms of tremor improvement (kinetic at 6 weeks and postural at 6, 12,
and 16 weeks) that was more prominent in the high-dose group. There
was dose-dependent hand weakness in a majority of the patients. Both
blinded studies considered the fixed-dose design a weakness of the
protocol and recommended a customized approach for future trials.
Rest tremor
Rest tremor is the hallmark of Parkinson’s disease (PD). A number
of patients with PD also demonstrate postural tremor. In an open
study, Pullman et al.51 first reported a mean of 13% improvement of
parkinsonian rest tremor after onabotulinumtoxinA injection into the
forearm muscles. Overall, 35.7% of the patients responded to the
treatment with onabotulinumtoxinA. In the same year, Henderson
et al.52 compared the effect of 25 and 50 units of onabotulinumtoxinA
with placebo in 17 PD patients in a single blind study. In the botulinum
toxin group, 40% showed improvement of the rest tremor and 57%
demonstrated improvement of postural tremor, twice that of the
placebo group. The authors noted the development of hand weakness
in nine of 17 patients and commented on the need for better-designed
studies to avoid hand weakness. Recently, the preliminary results of a
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double-blind placebo-controlled study of incobotulinum toxin A in PD
tremor was published by the Yale group in an abstract form.53 In this
customized double-blind, crossover study, 100–120 units of incobotuli-
numtoxinA was injected into eight to 10 different forearm and hand
muscles of 30 patients and the results were compared with a placebo
over 14 weeks of observation. Both tremor subsets of the Unified
Parkinson’s Disease Rating Scale (UPDRS) and National Institute of
Health (NIH) tremor scales improved significantly (2 grades or more)
in the incobotulinumtoxinA (p50.001). Marked improvement in
‘‘patient global impression of change’’ was reported by eight patients in
the toxin group in contrast to none among patients in the placebo
group (p50.007). Moderate to severe weakness of the hand was noted
in two patients (6%) in the incotoxin group and one patient (3%) in the
saline group.
There are positive case observations on the use of botulinum toxins
in other types of tremors such as essential voice tremor, essential head
tremor, palatal tremor and primary hand tremor; These await
confirmation by blinded studies.
Tics and Tourette syndrome
Tics are sudden, rapid, recurrent, non-rhythmic movements (motor
tics) or sounds (phonic tics).54 Motor tics can be clonic, dystonic,
or tonic and manifest with simple or complex symptomatology.
Complex tics are often seen in Tourette syndrome, which also includes
vocalization and behavioral problems (obsessive compulsive disorder,
attention deficit). Dopamine-blocking agents (fluphenazine and
aripiprazole), a-2-agonists such as clonidie and guanfacine and/or
dopamine-depleting drugs such as tetrabenazine may improve motor
and vocal tics. Recalcitrant tics may respond to deep brain stimula-
tion,55 yet still some fail to respond to both medical and surgical
approaches.
Jankovic56 first reported moderate improvement of blinking and
dystonic tics in 10 patients after intramuscular onabotulinumtoxinA
administration in 1994. Subsequently, in the year 2000, he and his co-
workers published57 a case series of 35 patients in whom the same
toxin was injected for treatment of motor tics in different facial and
cervical muscles including the vocal cords. The improvement rate was
78% on a global rating scale and 84% for premonitory sensation
(urge). In another open study,58 investigators evaluated the efficacy of
bilateral injection of onabotulinumtoxinA (2.5 units) into the vocal
cords of 22 patients with vocal tics. Using Hopkins Vocal Tic Scale,
93% of the patients improved and another 50% demonstrated
improvement of the ‘‘interference in life scale.’’ Finally, Marras
et al.59 conducted a double-blind, placebo-controlled, crossover study
in 18 patients with motor tics of the facial, neck, and shoulder muscles.
A statistically significant improvement compared with placebo was
noted in 39% of the patients with motor tics. A low statistical power
because of the small number of patients may have accounted for non-
significant values obtained for the changes in quality of life in this
study. Although limited, the results of the aforementioned studies
indicate that botulinum toxins can improve focal motor and phonic
tics46 and necessitate larger clinical trials in this area to be conducted.
History of botulinum toxin treatment in uncommon movement
disorders
Two uncommon movement disorders in which botulinum toxin
data are available are selected for this review. The rationale for
selecting these two is twofold: 1) the literature on others (myokymia,
paretic facial contracture, chin tremor, etc.) is limited to one or more
single case reports; 2) these two selected movement disorders are often
more disabling than others.
Spinal myoclonus
Spinal myoclonus (spinal segmental myoclonus) is caused by a lesion
or dysfunction of one or more segment(s) of the spinal cord. It can
result from diverse causes including tumor, trauma, infection, and
demyelination.60 Spinal myoclonus is often rhythmic, involving one or
both legs. In some cases, it is associated with significant leg pain and
discomfort. Treatment of spinal myoclonus is difficult and often
unsuccessful. Clonazepam and valproic acid can be partially effective.
With clonazepam, relief may require doses of up to 6 mg/day.
Leviteracetam 500–1000 mg/day has helped a limited number of
patients.
Polo and Jabbari61 first reported marked improvement of painful
spinal myoclonus after intramuscular administration of onabotuli-
numtoxinA. The patient was a 16-year-old female with Scimitar
syndrome (vascular cardiopulmonary anomaly) who suffered from
sudden paraplegia secondary to an acute mid-thoracic spinal cord
infarct. The right leg remained paralyzed and atrophic but the left leg
gradually regained near full strength. After 4 years, however, she
developed rhythmic and painful rhythmic involuntary movements
of the left rectus and vastus muscles. Injection of 280 units of
onabotulinumtoxinA into the left quadriceps (rectus 100, V. medialis
90, and V. lateralis 90 units) markedly reduced the movements and
stopped the pain. The effect lasted 5 months and was duplicated after a
second injection. In a subsequent report, a case of stimulus sensitive
spinal myoclonus was reported who responded well to intramuscular
administration of botulinumtoxin A.62 Another case report described a
26-year-old female with segmental C1–C3 spinal myoclonus in whom
injection of botulinumtoxin A into the infrahyoid and cervical
paraspinal muscles stopped the movements. The effect lasted for
5 months.63 In a recent review article on propriospinal myoclonus, the
authors reported 20 patients from the world literature who had
responded to botulinum toxin treatment.64
Painful/painless legs, moving toes and painful/painless hands,
moving fingers
This entity was first described by Spillane et al.65 in 1971 and
designated as ‘‘painful leg moving toes’’. Other similar entities, but less
common, include painless leg moving toes and painful or painless hand
moving fingers.66 A significant majority of these patients have a history
of damage to the peripheral nervous system (peripheral nerve, plexus,
root) preceding the onset of involuntary limb movements/pain by
months or years. However, there is evidence for central mechanisms
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based on electrophysiology and the clinical course; for example, similar
movements may develop in the contralateral leg.67,68 Movements are
semi-rhythmic and irregular and EMG often shows periodic discharges
similar to myokymia.67 In some patients, the limb pain is severe and
disabling. Pharmacological treatment is often not helpful.68,69
In 2007, Singer and Papapetropoulos70 first reported 80% improvement
of bilateral involuntary finger movements with onabotulinumtoxinA injec-
tion into flexor digitorum superfecialis (12.5 units) in a 20-year-old
female who had bilateral painless hand, moving fingers. In 2008,
Eisa et al.71 first described marked improvement of pain and involun-
tary toe movements in two patients with painful legs, moving toes.
OnabotulinumtoxinA was injected under EMG guidance into the flexor
digitorum brevis and gastrocnemius muscles bilaterally in one patient
(total 100 units) and in the flexor digitorum longus (total 50 units) in the
other patient. In subsequent years, a similar experience with botulinum
toxins in painless leg moving toes was reported by others in regard to
both movement and pain improvement.72
Owing to the infrequency of spinal myoclonus and painful/painless
limb disorders, it is unlikely that the efficacy of botulinum toxins can be
studied in these conditions under a randomized, blinded, placebo-
controlled protocol that includes a sizeable number of patients.
Table 1 demonstrates the time lines for development of botulinum
toxin as a therapeutic agent. Table 2 shows the first double-blind
studies reported for botulinum toxin treatment in movement disorders.
Table 1. The Historical Timelines on Emergence of Botulinum Toxin as a Therapeutic Agent
1817–1822 Observations and seminal writings of Justinus Kerner on symptoms of botulism
outbreaks in Germany
1897 Emile Van Ermengem finds the responsible agent for botulism and calls it bacillus
botulinum
1924 The name clostridium botulinum was introduced by Ida Bengton
1942–1946 Carl Lamanna and Edward Schantz purify the toxin and prepare it in crystalline
form
1946 Schantz produces a large amount of this toxin and makes it available for clinical
research
1964–1966 Drachman demonstrates the paralytic effects of botulinum toxin and its physiology
in an animal model (chicks embryos)
Late 1960s to early 1970s Allen Scott an ophthalmologist, further studies the paralytic effects of the
botulinum toxin in primates
1973 Scott publishes the first paper on weakening of extraocular muscles of monkeys
1979 FDA approves conducting research with botulinum toxin in human subject
1989 FDA Approves, Allergan’s Oculinum (later called Botox, onabotulinum toxin A)
for treatment of strabismus, blepharospasm and hemifacial spasm
Table 2. First Randomized, Double-blind, Placebo-controlled Studies with Botulinum Toxins in Movement Disorders
Movement Disorder Authors Year Type of Toxin
Cervical dystonia Tsui et al.31 1986 OnabotulinumtoxinA
Blepharospasm Jankovic and Orman15 1987 OnabotulinumtoxinA
Hemifacial spasm Yoshimura et al.38 1992 OnabotulinumtoxinA
Task-specific dystonia Cole et al.40 1995 OnabotulinumtoxinA
Essential tremor Jankovic and Schwartz48 1996 OnabotulinumtoxinA
Simple motor tics Marras et al.59 2001 OnabotulinumtoxinA
Rest tremor Shivam et al.53 2016 IncobotulinumtoxinA
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Conclusion
This historical review identifies early contributions that were
essential for introduction and establishment of botulinum toxins for
treatment of movement disorders. Botulinum toxins are now
established as the first line of treatment for HFS, blepharospasm,
and laryngeal dystonia and are considered a major treatment modality
for limb dystonias, including the task-specific dystonias. Early data on
essential tremor and Parkinson tremor and on tics are also encouraging
and reflect a potential for future application.
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